Welcome

RAS oncogenes were considered undruggable for decades. Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021. Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options.

The goal of this symposium is to highlight recent advances in RAS biology and novel therapeutic strategies to foster scientific discussions as to how the field can advance to address future challenges. At the same time, we plan to nurture dialogue between clinicians, preclinical as well as industrial researchers to envision how current research may guide future clinical practice.

We are inviting basic researchers, clinicians, and pharmaceutical scientists to join us in Salamanca, Spain, in September 2023, at our symposium Targeting RAS: new avenues and challenges.

Targeting RAS
Symposium

13th – 15th
September
2023

Welcome

Targeting RAS, new challenges and avenues. RAS oncogenes were considered undruggable for decades.

Yet, this situation changed considerably with the development of new drugs targeting different mutant isoforms culminating in the approval of the first RAS-targeting drug in 2021.

Nevertheless, a better understanding of the basic principles of RAS signaling may guide the development of improved therapeutic options.
The goal of this symposium is to highlight recent advances in RAS biology and novel therapeutic strategies to foster scientific discussions as to how the field can advance to address future challenges.

At the same time, we plan to nurture dialogue between clinicians, preclinical as well as clinical industrial researchers to envision how current research may guide future clinical practice.

Program

13th september
14th september
15th september
13th september
13 September 2023
08:00

Registration

13 September
Time:  08:00 - 09:00
Location: 
08:45

Opening presentation / Welcome speech (Eugenio Santos, Director, Centro de Investigación del Cáncer, Salamanca, Spain)

13 September
Time:  08:45 - 09:00
Location: 
09:00

SESSION 1: RAS DRIVEN MECHANISMS DURING TUMOUR INITIATION & PROGRESSION - Chairperson: Eugenio Santos

13 September
Time:  09:00 - 10:30
Location: 
09:00

Shiva Malek (Novartis Institutes for Biomedical Research, Boston, USA)

Targeting RAS
13 September
Time:  09:00 - 09:30
Location: 
Speaker:  Shiva Malek
09:30

RAS mutation tropism

Targeting RAS
13 September
Time:  09:30 - 10:00
Location: 
Speaker:  Christopher Counter
10:00

Dafna Bar-Sagi (NYU Langone Health, New York, USA)

Targeting RAS
13 September
Time:  10:00 - 10:30
Location: 
Speaker:  Dafna Bar Sagi
10:30

Short talk selected from abstracts

13 September
Time:  10:30 - 10:45
Location: 
10:45

Coffee break

13 September
Time:  10:45 - 11:15
Location: 
11:15

SESSION 2: RAS & TUMOUR MICROENVIRONMENT - Chairperson: Esther Castellano

13 September
Time:  11:15 - 12:45
Location: 
11:15

Developing rational approaches to targeting RAS in combination with immune regulators

Targeting RAS
13 September
Time:  11:15 - 11:45
Location: 
Speaker:  Julian Downward
11:45

David Tuveson (Cold Spring Harbor Laboratory, New York, USA)

Targeting RAS
13 September
Time:  11:45 - 12:15
Location: 
Speaker:  David Tuveson
12:15

Fine tuning adhesion to control cancer

Targeting RAS
13 September
Time:  12:15 - 12:45
Location: 
12:45

Short talk selected from abstracts

13 September
Time:  12:45 - 13:00
Location: 
13:00

Lunch & poster session

13 September
Time:  13:00 - 14:30
Location: 
14:30

SESSION 3: RAS MEMBRANE DYNAMICS & STRUCTURAL INSIGHTS - Chairperson: David Santamaría

13 September
Time:  14:30 - 16:00
Location: 
14:30

How can same-gene mutations promote both cancer and developmental disorders?

Targeting RAS
13 September
Time:  14:30 - 15:00
Location: 
Speaker:  Ruth Nussinov
15:00

Chiara Ambrogio (University of Torino, Torino, Italy)

Targeting RAS
13 September
Time:  15:00 - 15:30
Location: 
Speaker:  Chiara Ambrogio
15:30

Drug combinations with novel PDE6D inhibitors release differentiation block of oncogenic KRAS

Targeting RAS
13 September
Time:  15:30 - 16:00
Location: 
Speaker:  Daniel Abankwa
16:00

Short talk selected from abstracts

13 September
Time:  16:00 - 16:15
Location: 
16:15

Coffee break

13 September
Time:  16:15 - 16:45
Location: 
16:45

SESSION 4: RAS ISOFORMS AND SUPERFAMILY - Chairperson: Piero Crespo

13 September
Time:  16:45 - 18:15
Location: 
16:45

Ras variant abundance and biology

Targeting RAS
13 September
Time:  16:45 - 17:15
Location: 
Speaker:  Ian Prior
17:15

Pablo Rodríguez-Viciana (University College London (UCL), London, UK)

Targeting RAS
13 September
Time:  17:15 - 17:45
Location: 
17:45

Some “out of the box” of RAS superfamily GTPases in cancer

Targeting RAS
13 September
Time:  17:45 - 18:15
Location: 
Speaker:  Xosé R. Bustelo
18:15

Short talk selected from abstracts

13 September
Time:  18:15 - 18:30
Location: 
18:30

Day 1 round table

13 September
Time:  18:30 - 19:15
14th september
14 September 2023
09:00

SESSION 5: NOVEL THERAPEUTIC APPROACHES (PRECLINICAL PERSPECTIVE) - Chairperson: Matthias Drosten

14 September
Time:  09:00 - 11:00
Location: 
09:00

Rene Bernards (Netherlands Cancer Institute, Amsterdam, Netherlands)

Sala Mayor, Fonseca
Targeting RAS
14 September
Time:  09:00 - 09:30
Location:  Sala Mayor, Fonseca
Speaker:  René Bernards
09:30

Targeting KRAS signalling

Targeting RAS
14 September
Time:  09:30 - 10:00
Location: 
Speaker:  Mariano Barbacid
10:00

Drug repurposing strategies for the treatment of mutant KRAS cancers

Targeting RAS
14 September
Time:  10:00 - 10:30
Location: 
Speaker:  Silve Vicent
10:30

Targeting kras and it effectors in both normal and transformed colorectal epithelium.

Targeting RAS
14 September
Time:  10:30 - 11:00
Location: 
Speaker:  Owen Sansom
11:00

Short talk selected from abstracts

14 September
Time:  11:00 - 11:15
Location: 
11:15

Coffee break

14 September
Time:  11:15 - 11:45
Location: 
11:45

SESSION 6: NOVEL THERAPEUTIC APPROACHES (CLINICAL PERSPECTIVE) - Chairperson: Pilar Garrido

14 September
Time:  11:45 - 13:45
Location: 
11:45

Kevan Shokat (Howard Hughes Medical Institute, Maryland, USA & University of California San Francisco (UCSF), San Francisco, USA & University of California (UC Berkeley), Berkeley, USA)

Targeting RAS
14 September
Time:  11:45 - 12:15
Location: 
Speaker:  Kevan Shokat
12:15

Ernest Nadal (Catalan Institute of Oncology (ICO); Bellvitge Biomedical Research Institute (IDIBELL); L'Hospitalet, Barcelona, Spain)

Targeting RAS
14 September
Time:  12:15 - 12:45
Location: 
Speaker:  Ernest Nadal
12:45

Luis Paz Ares (Hospital Universitario 12 de Octubre, Madrid, Spain)

Targeting RAS
14 September
Time:  12:45 - 13:15
Location: 
Speaker:  Luis Paz-Ares
13:15

Applied biobanking to validate clinical vulnerabilities in RAS lung cancer variants

Targeting RAS
14 September
Time:  13:15 - 13:45
Location: 
Speaker:  Colin Lindsay
13:45

Short talk selected from abstracts

14 September
Time:  13:45 - 14:00
Location: 
14:00

Lunch & poster session

14 September
Time:  14:00 - 15:30
Location: 
15:30

SESSION 7: NOVEL THERAPEUTIC APPROACHES (PHARMACEUTICAL PERSPECTIVE) - Chairperson: Julian Downward

14 September
Time:  15:30 - 17:30
Location: 
15:30

Mathew Holderfield (Revolution Medicines, Redwood City, USA)

Targeting RAS
14 September
Time:  15:30 - 16:00
Location: 
Speaker:  Mathew Holderfield
16:00

Progress on selective targeting of KRAS mutant alleles and emerging clinical implications

Targeting RAS
14 September
Time:  16:00 - 16:30
Location: 
Speaker:  James Christensen
16:30

A novel molecular mechanism to inhibit PIK3CA action, drive profound tumor growth inhibition and avoid hyperglycemia

Targeting RAS
14 September
Time:  16:30 - 17:00
Location: 
Speaker:  Pedro Beltran
17:00

Targeting KRAS via SOS1: Parallel Fragment Screening and HTS Approach

Targeting RAS
14 September
Time:  17:00 - 17:30
Location: 
Speaker:  Barbara Nicke
17:30

Rati Verma (Amgen, Thousand Oaks, California, USA)

Targeting RAS
14 September
Time:  17:30 - 18:00
Location: 
Speaker:  Rati Verma
18:00

Coffee break

14 September
Time:  18:00 - 18:30
Location: 
18:30

SESSION 8: TREATMENTS & COMBINATIONS TO COME (ROUND TABLE) - Chairperson: René Bernards

14 September
Time:  18:30 - 19:15
Location: 
18:30

Participants from pharma, clinic and academia (TBD)

14 September
Time:  18:30 - 19:15
Location: 
20:30

Meeting dinner

14 September
Time:  20:30 - 22:30
15th september
15 September 2023
09:00

SESSION 9: RAS SYSTEMS BIOLOGY & NOVEL SIGNALLING FEATURES (I) - Chairperson: Silve Vicent

15 September
Time:  09:00 - 10:30
Location: 
09:00

A perfect storm - Formation of Ras - Raf signalosome and its implications

Targeting RAS
15 September
Time:  09:00 - 09:30
Location: 
Speaker:  Yibing Shan
09:30

Three Rs: RNA Regulates RAS-ERK signals

Targeting RAS
15 September
Time:  09:30 - 10:00
Location: 
Speaker:  Piero Crespo
10:00

Proteomic profiling of KRAS signaling; Context, CAFs and Combinations

15 September
Time:  10:00 - 10:30
Location: 
Speaker:  Udai Banerji
10:30

Short talk selected from abstracts

15 September
Time:  10:30 - 10:45
Location: 
10:45

Coffee break

15 September
Time:  10:45 - 11:15
Location: 
11:15

SESSION 10: RAS SYSTEMS BIOLOGY & NOVEL SIGNALLING FEATURES (II) - Chairperson: Mariano Barbacid

15 September
Time:  11:15 - 12:45
Location: 
11:15

Back to the future: the role of RAF kinases in RAS signaling and transformation

Targeting RAS
15 September
Time:  11:15 - 11:45
Location: 
Speaker:  Walter Kolch
11:45

Targeting the KRAS-ERK-MYC signaling network for the treatment of KRAS-mutant pancreatic cancer

Targeting RAS
15 September
Time:  11:45 - 12:15
Location: 
Speaker:  Channing J. Der
12:15

Ras-effector networks in (patho)physiological contexts

Targeting RAS
15 September
Time:  12:15 - 12:45
Location: 
Speaker:  Christina Kiel
12:45

Short talk selected from abstracts

15 September
Time:  12:45 - 13:00
Location: 
13:00

SESSION 11: CLOSING LECTURE

15 September
Time:  13:00 - 13:45
Location: 
13:00

The End of KRAS cancers?

Targeting RAS
15 September
Time:  13:00 - 13:30
Location: 
Speaker:  Frank McCormick
13:45

Lunch & end of meeting

15 September
Time:  13:45 - 15:00

Speakers

Colin Lindsay

Christie NHS Foundation Trust, University of Manchester, Manchester, UK

Ernest Nadal

Ernest Nadal (Catalan Institute of Oncology (ICO); Bellvitge Biomedical Research Institute (IDIBELL); L'Hospitalet, Barcelona, Spain)

Frank McCormick

National Cancer Institute RAS Initiative (Frederick National Laboratory for Cancer Research, Frederick, MD) & University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, USA.

Ian Prior

University of Liverpool, Liverpool, UK

Kevan Shokat

Howard Hughes Medical Institute, Maryland, USA & University of California San Francisco (UCSF), San Francisco, USA & University of California (UC Berkeley), Berkeley, USA.

Owen Sansom

Beatson Institute for Cancer Research, Glasgow. UK

Shiva Malek

Novartis Institutes for Biomedical Research, Boston, USA

Walter Kolch

Systems Biology Ireland, University College Dublin, Dublin, Ireland

Registration

Event Location

palacio congresos de salamanca

Palacio de Congresos Salamanca

Cuesta de Oviedo, S/N, 37008 Salamanca
Suitable for conferences, performances and shows.
 

Targeting RAS – New challenges and avenues  has been made possible thanks to:

logo-CIC
1280px-Logotipo_del_CSIC
marca-UniversidadSalamanca-color
Do you want to enjoy and benefit from the knowledge of world-renowned researchers?

Any questions?
Ask us

If you need additional information or would like to know any specific details, please contact us.